

Biocan Novel DHPPi/L4R, Lyophilisate and solvent for suspension for injection

Authorised

- Canine distemper virus, strain CDV Bio 11/A, Live
- Canine adenovirus 2, strain CAV-2-Bio 13, Live
- Canine parvovirus, type 2b, strain CPV-2b Bio 12/B, Live
- Canine parainfluenza virus, strain CPIV-2-Bio 15, Live
- Leptospira interrogans, serovar Icterohaemorrhagiae, strain MSLB 1089, Inactivated
- Leptospira interrogans, serovar Canicola, strain MSLB 1090, Inactivated
- Rabies virus, strain SAD Vnukovo-32, Inactivated
- Leptospira kirschneri, serovar Grippotyphosa, strain MSLB 1091, Inactivated
- Leptospira interrogans, serovar Bratislava, strain MSLB 1088, Inactivated

Product identification

Medicine name:

Biocan Novel DHPPi/L4R, Lyophilisate and solvent for suspension for injection

Active substance:

Canine distemper virus, strain CDV Bio 11/A, Live

Canine adenovirus 2, strain CAV-2-Bio 13, Live

Canine parvovirus, type 2b, strain CPV-2b Bio 12/B, Live

Canine parainfluenza virus, strain CPiV-2-Bio 15, Live
Leptospira interrogans, serovar Icterohaemorrhagiae, strain MSLB 1089, Inactivated
Leptospira interrogans, serovar Canicola, strain MSLB 1090, Inactivated
Rabies virus, strain SAD Vnukovo-32, Inactivated
Leptospira kirschneri, serovar Grippotyphosa, strain MSLB 1091, Inactivated
Leptospira interrogans, serovar Bratislava, strain MSLB 1088, Inactivated

Target species:

Dog

Route of administration:

Subcutaneous use

Product details

Active substance and strength:

Canine distemper virus, strain CDV Bio 11/A, Live
5.10 log₁₀ 50% tissue culture infectious dose / 1.00 Dose

Canine adenovirus 2, strain CAV-2-Bio 13, Live
5.30 log₁₀ 50% tissue culture infectious dose / 1.00 Dose

Canine parvovirus, type 2b, strain CPV-2b Bio 12/B, Live
6.60 log₁₀ 50% tissue culture infectious dose / 1.00 Dose

Canine parainfluenza virus, strain CPiV-2-Bio 15, Live
5.10 log₁₀ 50% tissue culture infectious dose / 1.00 Dose

Leptospira interrogans, serovar Icterohaemorrhagiae, strain MSLB 1089, Inactivated
51.00 Antibody microagglutination-lytic reaction / 1.00 Dose

Leptospira interrogans, serovar Canicola, strain MSLB 1090, Inactivated
51.00 Antibody microagglutination-lytic reaction / 1.00 Dose

Rabies virus, strain SAD Vnukovo-32, Inactivated
2.00 international unit(s) / 1.00 Dose

Leptospira kirschneri, serovar Grippotyphosa, strain MSLB 1091, Inactivated
40.00 Antibody microagglutination-lytic reaction / 1.00 Dose

Leptospira interrogans, serovar Bratislava, strain MSLB 1088, Inactivated
51.00 Antibody microagglutination-lytic reaction / 1.00 Dose

Pharmaceutical form:

Lyophilisate and solvent for suspension for injection

Anatomical therapeutic chemical veterinary (ATCvet) codes:

QI07AJ06

Legal status of supply:

Veterinary medicinal product subject to veterinary prescription

Authorisation status:

Valid

Authorised in:

Latvia

Package description:

Available only in [Latvian](#)

Available only in [Latvian](#)

Available only in [Latvian](#)

Additional information

Entitlement type:

Marketing Authorisation

Legal basis of product authorisation:

Full application (Article 12(3) of Directive No 2001/82/EC)

Marketing authorisation holder:

Bioveta a.s.

Marketing authorisation date:

28/07/2014

Manufacturing sites for batch release:

Bioveta a.s.

Responsible authority:

Food And Veterinary Service

Authorisation number:

V/DCP/14/0043

Date of authorisation status change:

28/07/2014

Reference member state:

Czechia

Procedure number:

CZ/V/0119/001

Concerned member states:

Bulgaria Croatia Cyprus Estonia Hungary Latvia Lithuania Poland Romania
Slovakia Slovenia

To consult adverse reactions on veterinary medicinal products please go to
www.adrreports.eu/vet

Documents

Combined File of all Documents

This document does not exist in this language (English). You can find it in another language below.

Summary of Product Characteristics

Package Leaflet

Labelling